Profile | GDS2987 / GI_40217802-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 41.4 | 68 |
GSM215244 | HMVEC_vehicle_rep2 | 4.5 | 12 |
GSM215253 | HMVEC_vehicle_rep3 | 6.5 | 22 |
GSM215254 | HMVEC_atorvastatin_rep1 | 20.4 | 47 |
GSM215282 | HMVEC_atorvastatin_rep3 | 31 | 56 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 25 | 45 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 6.1 | 10 |
GSM215294 | HMVEC_SLx2119_rep1 | 8.5 | 30 |
GSM215295 | HMVEC_SLx2119_rep2 | 15.8 | 31 |
GSM215296 | HMVEC_SLx2119_rep3 | 40.2 | 55 |
GSM215297 | PASMC_vehicle_rep1 | 24.1 | 36 |
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 16.1 | 28 |
GSM215312 | PASMC_atorvastatin_rep2 | 14.5 | 23 |
GSM215313 | PASMC_atorvastatin_rep3 | 6.6 | 10 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 28.8 | 44 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 12.5 | 25 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 7.4 | 14 |
GSM215329 | PASMC_SLx2119_rep3 | 23.1 | 41 |
GSM215330 | Fibroblasts_vehicle_rep1 | 104.3 | 75 |
GSM215331 | Fibroblasts_vehicle_rep2 | 71 | 72 |
GSM215332 | Fibroblasts_vehicle_rep3 | 86.5 | 74 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 63.7 | 71 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 61 | 70 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 74.7 | 72 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 68.8 | 72 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 50 | 69 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 29.8 | 60 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 27.2 | 58 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 36.2 | 64 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 94.1 | 74 |